156 results
Page 2 of 8
SC TO-C
l0x44qxq
3 Oct 23
Information about tender offer
4:30pm
SC TO-C
EX-99.1
ix5eht7
3 Oct 23
Information about tender offer
4:30pm
SC14D9C
17iv3q ijsrf5bxnb6
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-99.4
rdsi3vq1n4wb2wjsf1
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-2.1
vhrvr upl7kcr
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
hywl925zfjzt79dv
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.4
uq2lzfyikakeni
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-2.1
lw9ktdxnign4l
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.1
nnp479mu0cmn5 ih
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
l0fn722
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-1.1
q16v5jj4lu4g5ax
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
424B5
rtwma2
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
ulj ltigt0h1z
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
xmdye3ntau8 v4
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am